The Consortium of Multiple Sclerosis Centers Annual Meeting is the leading research and educational conference for multiple sclerosis healthcare professionals of all disciplines in North America.
Alemtuzumab Maintains Long-Term Efficacy in MS, Shows Superiority to Interferon Beta
May 30th 2019Follow-up data extending out to 8 years suggest that both clinical and MRI outcomes are better with alemtuzumab (Lemtrada) than interferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Higher-Efficacy DMTs May Have Favorable Effect on Depression in MS
May 29th 2019Given that depression is a common symptom in patients with MS and is associated with increased morbidity and mortality, the investigators examined the effects of lower-efficacy DMTs and higher-efficacy DMTs on depression.
Nonadherence to Disease-Modifying Treatment in MS Has Significant Clinical and Economic Effects
May 29th 2019In order to better understand the clinical and economic impacts of nonadherence to disease-modifying therapy, the investigators conducted a cost-consequence analysis among patients taking once- or twice-daily DMTs.
Cladribine Reduces MRI Lesions Across Subgroups in ORACLE-MS Study
May 28th 2019The subgroups were defined by baseline characteristics that are known to be potential modifiers of risk to conversion to clinically-definite multiple sclerosis, including age, gender, first classification of demyelinating event, presence of T1 Gd+ lesions, and number of active T2 lesions.